CD274 and neoplasm: In addition, all survivors in the SC144@HABN + anti-PD-L1 combo group were resistant to re-challenge with 4T1 tumor cells performed on day 50, demonstrating establishment of long-term anti-tumor immunity (Fig. 5g).